Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity
- 1 April 2018
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 150, 809-816
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81473078)
This publication has 24 references indexed in Scilit:
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer AgentJournal of Medicinal Chemistry, 2011
- MET signalling: principles and functions in development, organ regeneration and cancerNature Reviews Molecular Cell Biology, 2010
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor ActivityMolecular Cancer Therapeutics, 2010
- c-Met is essential for wound healing in the skinJournal of Cell Biology, 2007
- Cancer therapy: can the challenge be MET?Trends in Molecular Medicine, 2005
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb budNature, 1995
- The human met oncogene is related to the tyrosine kinase oncogenesNature, 1985